EvaluatePharma Heading
The Integrated Forecasting and Analysis Tool
EvaluatePharma
 
  Login Now
Chugai 
EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service.

A small selected sample of reports and related news headlines for Chugai are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Chugai, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers

  Annual Sales WW - Sales Growth per Year (%)
  Rank Product Generic Name Pharmacological Class 2006 2007 2007
Chugai 1 Epogin/EPOCH epoetin beta Erythropoietin 545 466   (15%)  
  2 Neutrogin/Granocyte lenograstim Colony stimulating factor 310 333   7%  
  3 Sigmart nicorandil Potassium channel agonist 155 152   (2%)  
 
  Note: Shaded Cells  

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

 
  Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current)
Chugai - AVS (Antevas) Cardiovascular Cerebral & peripheral vasotherapeutics Hydroxyl radical scavenger Filed
  - ED-71 Musculoskeletal Bone calcium regulators Vitamin D3 analogue Phase III
  - GM-611 Gastro-Intestinal Anti-spasmodics & anti-cholinergics Motilin agonist Phase II

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Chugai
  2005 2006
 Valuation Measures
  Based on Latest Share Prices
     Valuing the Equity
       Market Capitalisation 8,992 8,992
       PE Ratio (diluted) - Normalised (x) 19.0 27.3
 
     Valuing the Enterprise
       Enterprise Value 7,645 7,645
       Free Cash Flow (Pre-Dividends) 556 172
       FCF Yield (%) 7.3% 2.2%
 
 Forecast Financials
  Income Statement
     Total Revenues 2,975 2,804
     Cost of Goods Sold (1,086) (1,144)
     S,G & A (714) (688)
     R&D (455) (470)
     Other Income/ Expense - Net 24 17
     EBIT - Normalised 744 518
     Net Interest & Financial Items 3 15
     Pre-tax Profits - Normalised 747 533
     Exceptionals 37 8
     Income Before Taxes 784 541
     Tax (284) (197)
     Tax Rate (%) 36.2% 36.3%
     Minorities (12) (14)
     Net Income - Reported 488 330
     Net Income - Normalised 470 326
 
  Per Share Data
     EPS - Diluted 0.88 0.60
     EPS - Basic 0.89 0.60
     EPS - Normalised (diluted) 0.85 0.59
     EPS - Normalised (basic) 0.85 0.59
     Avg. Shares Outstanding - Diluted 554.7 554.8
     Avg. Shares Outstanding - Basic 550.6 554.0
     DPS 0.29 0.26

NEWS - Selected Product News Headlines (as of 11 June 2008)

CellCept® and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus A Standard-Dose CNI   (Roche)   04-Jun-2008
Final Results of the CellCept® Spare the Nephron (STN) Study Shows Maintenance Therapy Is Associated with Improved Renal Function   (Roche)   02-Jun-2008
Pertuzumab With Herceptin Shows Impressive Results in Women With Advanced HER2-Positive Breast Cancer   (Roche)   30-May-2008
Actemra Inhibits Joint Damage and Improves Physical Function of Patients With Rheumatoid Arthritis   (Roche)   09-May-2008
Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C   (Roche)   28-Apr-2008
Actemra Approved in Japan to Treat Patients With Rheumatoid Arthritis   (Roche)   16-Apr-2008
Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Obtained Approval for Indications of Rheumatoid Arthritis, Polyarticular-Course Juvenile Idiopathic Arthritis and Systemic-Onset Juvenile Idiopathic Arthritis   (Chugai)   16-Apr-2008
OSI Pharmaceuticals Summarizes Data Presented at the Annual Meeting of the American Association for Cancer Research   (OSI Pharmaceuticals)   16-Apr-2008
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet   (Roche)   20-Mar-2008
Femara® Helps Protect Against Return of Breast Cancer Even When Treatment Starts Several Years After Completing Tamoxifen Therapy   (Novartis)   10-Mar-2008
Combination Therapy of Anti-cancer Agents, Xeloda®, Elplat® and Avastin®, and Monotherapy of Xeloda® Filed for Advanced or Recurrent Colorectal Cancer   (Chugai)   29-Feb-2008
Herceptin Approved in Japan for Early Treatment in Patients with HER2-Positive Breast Cancer   (Roche)   29-Feb-2008
Anti-Cancer Agent Herceptin® Obtained Approval for a New Indication for Adjuvant Therapy in Breast Cancer that Overexpresses HER2   (Chugai)   29-Feb-2008
Roche Responds to Announcement of “IDEAL” Hepatitis C Trial Results   (Roche)   14-Jan-2008
Anti-Cancer Agent Xeloda® Obtained Approval for a New Indication for Postoperative Adjuvant Chemotherapy for Colon Cancer and Overseas Dosage and Administration   (Chugai)   14-Dec-2007
On the Launch and Measures for Proper Use of the Anti-Cancer Agent Tarceva® Tablet   (Chugai)   14-Dec-2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan   (OSI Pharmaceuticals)   14-Dec-2007
"Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Filed for Rheumatoid Arthritis in Europe   (Chugai)   03-Dec-2007
"Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Filed for Rheumatoid Arthritis in the United States   (Chugai)   21-Nov-2007
Roche Submits Application for FDA Approval of Actemra for the Treatment of Rheumatoid Arthritis   (Roche)   21-Nov-2007
Newly Approved Administration of Cephalosporin Antibiotic Rocephin® for Injection: Once Daily Administration in Children   (Chugai)   19-Nov-2007
A Second Overseas Phase III Trial Data Demonstrates Efficacy of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients   (Chugai)   08-Nov-2007
Two Pivotal Phase III Studies for Roche’s ACTEMRA™ (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms   (Roche)   07-Nov-2007
Treatment with Pegasys Provides Hepatitis C Patients a Second Chance to Achieve a Cure After not Responding to Peg-intron   (Roche)   02-Nov-2007
Treatment with PEGASYS®/COPEGUS™ Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron®/Ribavirin   (Roche)   02-Nov-2007
Announcement of Supplemental Approval of Indication of Sigmart® Injection, a Treatment Drug for Unstable Angina Pectoris   (Chugai)   23-Oct-2007
Anti-Cancer Agent Tarceva® Tablet, Approved in Japan   (Chugai)   22-Oct-2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan   (OSI Pharmaceuticals)   22-Oct-2007
Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin® Injection" for Treatment of Chemotherapy-Induced Anemia   (Chugai)   27-Sep-2007
Herceptin Eradicates Tumours and May Reduce the Need for Mastectomies in Women With Inflammatory HER2-Positive Breast Cancer   (Roche)   26-Sep-2007
Positive Xeloda Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting   (Roche)   25-Sep-2007
Avastin Achieves Impressive Rate of Complete Resections (R0) in Patients With Advanced Colorectal Cancer   (Roche)   24-Sep-2007
New Study Shows Once-Monthly Boniva is as Clinically Effective as Once-Weekly Fosamax at Increasing Bone Mineral Density in Postmenopausal Women with Osteoporosis   (Roche)   20-Sep-2007
Actemra Monotherapy Demonstrates Significant Clinical Benefit in Patients with Rheumatoid Arthritis   (Roche)   25-Jul-2007
Actemra: Latest Phase III Study Shows Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis   (Roche)   10-Jul-2007
ACTEMRA™ (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis   (Roche)   10-Jul-2007
Safety Measures for Oseltamivir Phosphate and Chugai’s Future Approach   (Chugai)   18-Jun-2007
Overseas Phase III Trial Data Demonstrates Efficacy of "Actemra®," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients   (Chugai)   15-Jun-2007
Psoriasis Vulgaris Treatment Ethical Drug Topical Lotion Containing Active Vitamin D3 Launch of “Oxarol® Lotion”   (Chugai)   15-Jun-2007
ACTEMRA™ (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care   (Roche)   15-Jun-2007
Actemra: Roche’s Novel Rheumatoid Arthritis Drug Shows Substantial Benefits for Patients in OPTION Study   (Roche)   15-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

 
  Product Generic Name
Chugai Acetanol acebutolol
  Actemra tocilizumab
  Adcon-L carbohydrate polymer gel
  Adcon-T/N carbohydrate polymer gel
  AHM -
  Alfarol alfacalcidol
  Amoban zopiclone
  AN-132 -
  Avastin bevacizumab
  AVS (Antevas) nicaraven
  Benambax pentamidine isetionate
  Blutal chondroitin sulfate iron colloid
  BO-653 -
  Bonviva ibandronate
  CAL -
  Cefotax cefotaxime
  CellCept mycophenolate mofetil
  CHS13340 parathyroid hormone
  Copegus ribavirin
  CSG452 -
  ED-71 eldecalcitol
  Epogin/EPOCH epoetin beta
  Euglucon glyburide
  Evista raloxifene
  Femara letrozole
  Fortovase/Invirase saquinavir mesylate
  Furtulon doxifluridine
  Glyceol glycerol
  GM-611 mitemcinal fumarate
  Herceptin trastuzumab
  IC-351 tadalafil
  Inhibace cilazapril
  ITM-077 -
  Keiten cefpirome
  Kytril granisetron
  Lanirapid metildigoxin
  LY-139603 atomoxetine
  LY-335979 zosuquidar
  Menamin ketoprofen
  Mircera methoxy polyethylene glycol-epoetin beta
  MX-68 -
  NA808 -
  Natulan procarbazine
  Neutrogin/Granocyte lenograstim
  Omnitarg pertuzumab
  Optison/FS-69 -
  Oxarol maxacalcitol
  Oxarol Ointment/Oxarol Lotion maxacalcitol
  Pegasys peginterferon alfa-2a
  Pegasys & Copegus peginterferon alfa-2a & ribavirin
  Picibanil streptococcus pyogenes bacteria
  Pletaal cilostazol
  Preran trandolapril
  Prozac fluoxetine
  R1503 pamapimod
  R1594 ocrelizumab
  R1678 -
  R450 (alpha-1 agonist) dabuzalgron
  R483 (insulin sensitiser) edaglitazone
  Renagel sevelamer
  Rituxan rituximab
  Rocephin ceftriaxone
  Rohypnol flunitrazepam
  Rythmodan disopyramide
  Sigmart nicorandil
  Suvenyl sodium hyaluronate
  TA-270 -
  Tamiflu oseltamivir
  Tarceva erlotinib
  Taxotere docetaxel
  TP300 -
  TPO Agonist Minibody -
  Ulcerlmin sucralfate
  VAL valine
  Vesanoid tretinoin
  Xeloda capecitabine
  Xenical orlistat
  Xyotax paclitaxel poliglumex
  Zenol felbinac & menthol
 
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ® Generated at 14:00:31 (GMT) on 11-Jun-2008 © 2008 EvaluatePharma Ltd